论文部分内容阅读
目的：检测３０ 例肺癌患者和４３ 例正常人血小板相关抗体（ 简称 Ｐ Ａ Ｉｇ Ｇ、 Ｐ Ａ Ｉｇ Ｍ、 Ｐ Ａ Ｉｇ Ａ） 的含量，以探讨肺癌患者血小板异常的免疫机制及临床意义。方法：根据包被人 Ｉｇ Ｇ、 Ｉｇ Ｍ、 Ｉｇ Ａ 和 Ｐ Ａ Ｉｇ Ｇ、 Ｐ Ａ Ｉｇ Ｍ、 Ｐ Ａ Ｉｇ Ａ 与酶标抗体 Ｉｇ Ｇ、 Ｉｇ Ｍ、 Ｉｇ Ａ 竟争性结合的特征，采用 Ｅ Ｌ Ｉ Ｓ Ａ 法测定。结果：肺癌患者 Ｐ Ａ Ｉｇ Ｇ、 Ｐ Ａ Ｉｇ Ａ 值显著高于对照组（ Ｐ＜ ０ ．０１） ； Ｐ Ａ Ｉｇ Ｇ、 Ｐ Ａ Ｉｇ Ｍ、 Ｐ Ａ Ｉｇ Ａ 增高的阳性率分别为４０ ％ 、１３ ．３ ％ 、２０ ％ 。结论：肺癌患者血小板异常与免疫有关。
Objective: To detect the platelet-associated antibodies (abbreviated as P A Ig G, P A Ig M, P A Ig A) in 30 patients with lung cancer and 43 normal controls to investigate the immune mechanism and clinical significance of platelet abnormalities in patients with lung cancer. Methods: According to the characteristics of competitive binding between human Ig G, Ig M, Ig A and P A I G G, P A Ig M, P A Ig A and enzyme-labeled antibodies Ig G, Ig M, and Ig A, E was used. L I S A determination. Results: The P A Ig G and P A Ig A values in lung cancer patients were significantly higher than those in the control group (P < 0.01); the positive rates of P A Ig G, P A Ig M, and P A Ig A were 40%, respectively. 13. 3%, 20%. Conclusion: The platelet abnormalities in lung cancer patients are related to immunity.